The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use*; D015281:Cefmenoxime; D015311:Cefmetazole; D002438:Cefoperazone; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000627:therapeutic use; D015310:Cefotiam; D002441:Cefsulodin; D002442:Ceftazidime; D015296:Ceftizoxime; D002443:Ceftriaxone; D002511:Cephalosporins / Q000378:metabolism / Q000627:therapeutic use; D002513:Cephamycins / Q000627:therapeutic use; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D006801:Humans; D015378:Imipenem; D009070:Moxalactam; D047090:beta-Lactams / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; D047090:beta-Lactams; D015311:Cefmetazole; C029281:desacetylcefotaxime; D015378:Imipenem; D002443:Ceftriaxone; D002438:Cefoperazone; D015310:Cefotiam; D002442:Ceftazidime; D015296:Ceftizoxime; D015281:Cefmenoxime; D002439:Cefotaxime; D002441:Cefsulodin; D009070:Moxalactam